Find a Study

STUDY SEARCH RESULTS
  Notify Me When Search is Updated

1 study found for your search request:  6482-016

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Condition: Carcinoma, Hepatocellular, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma, Biliary Tract Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT04976634
Status: Recruiting
Has Enrolling Locations in US or Canada



Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site